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Summary The c-erbB-2 gene codes for a putative transmembrane protein, similar in structure to the
epidermal growth factor (EGF) receptor. Amplification of the gene has been described in a variety of human
adenocarcinomas and is particularly well documented in breast carcinoma. It has been suggested that
amplification is indicative of poor prognosis and, as such, is comparable with lymph node status as a
predictor of clinical outcome. This study examines the suggestion indirectly by an immunohistochemical
technique. Archival tissue from 195 patients with primary breast carcinoma was stained with the polyclonal
antibody 21N, raised to amino acids 1243-1255, the C-terminus of the predicted amino acid sequence of the
c-erbB-2 protein. Up to 10 year verified follow-up data were available on all patients. Staining compatible
with significant amplification was observed in 17 patients. Using the chi-squared test for trend a significant
correlation was found between staining and grade (P=0.04) but not with either node or receptor status. No
significant association was found between staining and clinical outcome although there was a tendency for
patients with stained tumours to have a worse prognosis. A Cox regression analysis was used to adjust for
node status and grade and still no correlation was revealed between staining and prognosis. However a study
of this size in which only a small number of patients have been found to have stained tumours does have
wide confidence limits. Comparable staining observed in in situ and infiltrating components of tumours
suggests that amplification is an early event in carcinogenesis. Similar staining in primary and subsequent
metastatic lesions was also noted. It is considered that further studies at both the DNA/mRNA and protein
levels are required to confirm the significance of c-erbB-2 amplification in human breast carcinoma.
The human proto-oncogene c-erbB-2 codes for a putative
transmembrane receptor protein similar in structure to the
epidermal growth factor (EGF) receptor, and has been
mapped to band q21 of chromosome 17 (Yamamoto et al.,
1986). It is the human analogue of the transforming gene
neu, originally found in rat neuroblastoma cell lines derived
from tumours induced by ethylnitrosourea (Bargmann et al.,
1985; Yamamoto et al., 1986). The gene has been shown to
be conserved in vertebrates, suggesting that it fulfils an
indispensable function (Semba et al., 1985). It codes for a
185-190 kilodalton glycoprotein and has the tyrosine kinase
activity characteristic of several known growth factor recep-
tors (Akiyama et al., 1986; Schechter et al., 1984).
The similarity of the c-erbB-2 protein to the EGF recep-
tor, which is known to be overexpressed on the surface of
cells of epidermoid carcinomas, prompted a search for
amplification of this gene in human carcinoma. Varying
degrees of amplification have been found in a range of
human adenocarcinomas, most notably breast carcinoma
(Semba et al., 1985; Yokota et al., 1986; van de Vijver et al.,
1987; Zhou et al., 1987). A causal relation was suggested by
Di Fiore et al. (1987) who showed that overexpression of the
gene product in NIH/3T3 cells in culture induced malignant
transformation at levels of gene product comparable to those
found in human breast tumour cells. The finding in neuro-
blastomas of a clear correlation between the extent of
amplification of an oncogene (n-myc) and aggressiveness of
disease (Seeger et al., 1985) has stimulated further studies.
Slamon and colleagues (1987) found c-erbB-2 amplification
to be a significant predictor of overall survival and time to
relapse. They demonstrated that amplification had prognos-
tic importance greater than most currently employed vari-
ables in those patients who were lymph node positive.
Concurrent with this work has been the production of
antibodies 20N and 21N raised to predicted amino acid
sequences of the gene product (Gullick et al., 1987). Gene
amplification has been shown to be closely associated with
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immunohistochemical assessment of the gene product in both
frozen and paraffin embedded material (Venter et al., 1987;
van de Vijver, 1988). A recent study by Gusterson et al.
(1988) indicates that the best association is with membrane
staining by the polyclonal antibody 21N raised to the
predicted amino acid sequence from residues 1243-1255 of
the open reading frame of c-erbB-2. This immunohisto-
chemical technique allows relatively simple retrospective
analysis of archival material. Such a study is described
below, evaluating tumours from patients on whom detailed
follow-up data are available.
Materials and methods
Patients
Primary mammary carcinomas from 195 female patients
were examined (age range 30-80 years; median 54 years).
The patients presented with operable primary breast carci-
noma between 1976 and 1978 and follow-up data to the time
of the study, obtained by careful review of clinical records,
were available on all. The diagnosis and date of recurrence
were determined in a standard manner according to the
criteria of Hayward et al. (1978). The cases were selected to
include patients both with and without pathologically
involved nodes at presentation. The material within each
group was further subdivided to include patients who had
subsequently recurred and those who had not. All patients
were treated by modified radical mastectomy. A small
number had received adjuvant melphalan chemotherapy.
This regimen was subsequently found not to affect the
clinical outcome (Rubens et al., 1983), so in our analysis
these cases were not treated separately. It is of note that in
the study of Slamon et al. (1987) 83% of patients received
various modalities of adjuvant treatment.
Five patients later developed a second primary tumour
in the contralateral breast and these tumours were also
examined, as were subsequent metastatic lesions from 15
other patients (11 cutaneous; 2 lymph node; 2 contralateral
breast).
Br. J. Cancer (1988), 58, 448-452c-erbB-2 ANTIBODY STAINING IN BREAST CANCER 449
Node status was known for all 195 patients, menstrual
status was known for 162 patients and parity was known for
180. Oestrogen receptor status was known for 172 patients
and progesterone receptor status for 90. Receptor status was
determined by the dextran-coated charcoal ligand binding
assay (King et al., 1977). At presentation the histological
type of all tumours was determined and all infiltrating ductal
carcinomas were graded according to the criteria of Bloom
and Richardson (1957).
Immunohistochemistry
For the present study 5 um sections of tumour were cut from
formalin-fixed paraffin-embedded material, in most cases
from one representative block but in some cases tissue from
more than one block was analysed. The sections were
dewaxed and placed in 0.1% hydrogen peroxide in methanol
0.01 M PBS pH 7.2 (5: 3) to block endogenous peroxidase
activity. After washing in tap water followed by PBS, the
sections were incubated with foetal calf serum/PBS (1:4) for
10min (in order to reduce non-specific staining with primary
antibody). Sections were then coated with 21N polyclonal
primary antibody at dilutions of 1/400 and 1/1000 in PBS
and left at room temperature overnight (preliminary work
was carried out using affinity purified 21N antibody, but for
this complete study whole rabbit serum was used at the
dilutions indicated). Next day sections were washed in
PBS for 10min and incubated with secondary antiserum (bio-
tinylated swine anti-rabbit immunoglobulin (Dakopatts)) at
1/500 dilution in PBS containing 15% foetal calf serum and
3% human serum for 30min and then rewashed in PBS.
Treatment with avidin-biotin peroxidase complex (Dakopatts
ABC complex) followed for 30 min. Peroxidase activity
was demonstrated using diamino-benzidine solution (Sigma)
and the nuclei were counterstained with haematoxylin.
The specificity of the reaction was confirmed by abolition
of staining following pre-incubation of antibody with the
immunising peptide (1 mgml-1). Negative controls in which
PBS replaced the primary antiserum were run with each
batch of stains. A previously identified strongly staining
tumour was used as a positive control. Inter and intra assay
consistency was maintained by running these positive and
negative controls with each batch of staining. Any assay in
which either control was unsatisfactory was repeated. In a
small number of positive tumours dilution studies were
performed in order to analyse the effect of varying concen-
trations of primary antibody on the distribution of staining.
Staining assessment
A variety of staining patterns was observed in the tumour
cells; both cytoplasmic and membrane staining were seen. In
all tumours which showed positive staining the majority of
cells exhibited the same pattern. Staining intensity of both
the cytoplasm and membranes was assessed separately for in
situ (when present) and infiltrating components according to
a graded scoring system - 0 (no staining), 1 (weak), 2
(moderate) and 3 (strong). To determine which of these
features was of greatest clinical relevance, different combi-
nations were assessed for each patient: firstly a composite
score giving equal weight to both cytoplasmic and membrane
staining; secondly a score noting the staining of the infiltrat-
ing tumour only; and thirdly a score reflecting membrane
staining only. Analysis using these different scores gave
similar results. Since it has been shown that membrane
staining has the best association with gene amplification, the
results below refer to membrane staining only. The use of 2
dilutions of antibody assisted in the assessment of staining
intensity. In the weak staining tumours membrane staining
was present but extremely faint at 1/1000 dilution, whilst the
strong stainers were similarly positive at both dilutions. All
cases were reviewed by two people, the few occasions of
disagreement were resolved by consultation. In the cases
where membrane stain was noted, its presence was confirmed
by repeat assay. Furthermore the intensity of staining in the
repeat assay was always similar to that in the original.
Statistics
The chi-squared (x2) test for trend was used to evaluate the
statistical significance of the relationship between staining
and other established prognostic variables. The relationship
between staining and clinical outcome was assessed using
actuarial survival curves and groups compared by the
logrank test (Peto et al., 1977). Cox regression analysis was
used to compare survival experience after adjusting for other
prognostic variables, using the programme BMDP2L
(Dixon, 1985).
Results
A range of staining patterns was seen. In some 70% of
tumours there was little or no staining of malignant cells.
The majority of the remaining tumours, however, showed
patchy staining. In only a small number was there a diffuse
pattern, with virtually all tumour cells positive.
All positive cells showed a granular cytoplasmic staining.
Some cases, in addition, showed an unequivocal membrane
localisation of stain (Figures I & 2) at both dilutions of
antibody used. Such membrane staining persisted at high
dilutions of primary antibody, even when cytoplasmic stain-
ing disappeared. Where single cells or small groups of cells
were set in a fibrous stroma, the stain often localised to the
region of the cell-stromal interface.
In a few cases patchy weak cytoplasmic staining was noted
in benign mammary tissue, including normal lobules, areas
of sclerosing adenosis and, in particular, apocrine
metaplasia.
Seventeen tumours (9%) showed strong or very strong
membrane staining (Figure 3). On the basis of previous
studies (Venter et al., 1987; Gusterson et al., 1988; van de
Vijver et al., 1988) such staining was interpreted as being
consistent with considerable c-erbB-2 amplification. Fourteen
of these tumours were infiltrating ductal (Figure 4), 1
infiltrating lobular, 1 mixed tubular and ductal and 1 mixed
tubular and cribriform. Forty-one other tumours of varying
histology showed weak membrane staining. The remainder
showed none.
One hundred and sixty-eight tumours were found to be of
infiltrating ductal type. More grade III tumours showed
some degree of 21N staining (41%) than grade 1 (25%) or II
(29%): x2 for trend=4.29, P=0.04. There was little relation
with node status: X2 for trend=0.16, P=0.7.
No significant association was observed between staining
and parity or menopausal status nor between any of the
other features examined. The results are summarised in
Table I.
No significant association was observed between staining
and disease-free interval, overall survival or post-relapse
survival, either considering three categories of staining or
combining the weak and strong staining groups. There was,
however, a tendency for patients with stained tumours to have
a worse prognosis, so Cox regression analysis was used to
adjust for node status and tumour grade. No difference was
found between the weak and strong staining groups so they
were combined. The relative hazard for the staining group
compared with the non-staining group was 1.25 for time to
recurrence (95% confidence interval: 0.77 to 2.02) and 0.85
for overall survival (95% confidence interval: 0.51 to 1.42).
Although no significant association was found between
staining and either time to recurrence or overall survival the
wide confidence intervals show that such an association
cannot be ruled out. Figures 5 & 6 show disease free interval
and overall survival curves for the patients, divided into 3
groups according to the nature of the membrane staining
(none, weak, moderate and strong).450 D.M. BARNES et al.
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Figure 1 Positive membrane staining of in situ duct carcinoma
(left) compared with unstained normal lobule (right), (x 125).
Figure 3 Cancerisation of a lobule showing strong positive
staining ( x 125). (All photomicrographs show staining at dilution
1/1000 of primary antibody).
Comparison of staining scores in the in situ and infiltrat-
ing components of the 118 tumours showing both patterns
of growth revealed no significant difference.
The staining in the metastatic lesions (11 cutaneous, 2
lymph node, 2 contralateral breast) was compared with the
respective primary tumours. Within the limits of sensitivity
of the technique, staining in the metastases did not differ
significantly from that in the primaries. Three of the pairs
were strongly stained; 12 stained weakly or not at all.
Five patients subsequently developed tumours in the con-
tralateral breast which were considered, on histological
grounds, to represent second primary growths. All were
observed to show similar staining reactions to the initial
primary carcinoma.
Figure 2 Detail of membrane staining. Comedo-type in situ duct
carcinoma ( x312).
Figure 4 Infiltrating ductal carcinoma ( x 125).
Discussion
Previous studies have demonstrated amplification of the
c-erbB-2 gene by means of Southern blotting in a proportion
ofhuman breast carcinomas: 28% in the series ofSlamon et al.
(1987) and 17% in that of Zhou et al. (1987). Antibodies
have now been raised to two synthetic peptides from the
predicted sequence of the human c-erbB-2 protein (Gullick et
al., 1987). Antibody 20N was raised against residues 1215-
1225 of the c-erbB-2 open reading frame and was used
inimmunohistochemical studies on frozen sections of mam-
mary carcinomas (Venter et al., 1987). The antibody 21N was
raised against amino acids 1243-1255, the predicted c-
terminus of the c-erbB-2 protein and this, together with 20N,
Table I Correlation between 21N staining, histological features and receptor status
Membrane staining
n None Weak Strong
Node status
0 positive nodes
1-3 positive nodes
>4 positive nodes
Grade of infiltrating ductal tumours
I
II
III
Oestrogen receptor
negative
positive
Progesterone receptor
negative
positive
195
102
58
35
168
28
72
68
172
42
130
90
37
53
72
42
23
21
56
40
18
14
9
5
13
18
12
2
3
2
3
10
23 13 6
92 27 11
24 6 7
33 13 7
Ns=not significant.
Ns
P=0.04
Ns
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Figure 5 Disease-free interval - no staining vs. weak staining vs.
strong or very strong staining, P>0.2.
a)
.1
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Figure 6 Survival from presentation - no staining vs. weak
staining vs. strong or very strong staining, P>0.3.
was used by Gusterson et al. (1988) in an immunohisto-
chemical study of c-erbB-2 in routinely fixed sections of
human breast cancer. The immunohistochemical studies were
accompanied by parallel assessment of the c-erbB-2 gene
using Southern blotting. It was found that c-erbB-2 amplifi-
cation was present in tumours which showed strong mem-
brane staining using the immunohistochemical technique.
The main advantage of the immunohistochemical
approach is that it allows rapid assessment of archival
material from patients with known follow-up. In addition,
tissue localisation of the gene product may be analysed. The
technique does, however, suffer from certain disadvantages.
Although a close association has been observed between
gene amplification, as determined by Southern blotting, and
overexpression of the gene product, as determined immuno-
histochemically (Gusterson et al., 1988; Venter et al., 1987)
the agreement is not perfect. In addition, one study with
21N and related antibodies revealed that, while recognising
the c-erbB-2 protein and not the structurally related EGF
receptor, 21N immunoprecipitates several additional bands
of varying size which have yet to be identified (Gullick et al.,
1987). Despite this apparent lack of specificity 21N staining
does, however, relate more closely to the gene amplification
than related antibodies (Gusterson et al., 1988). Van de
Vijver et al. (1988) have also raised an antibody to the c-
terminus of the c-erbB-2 protein (amino acids 1242-1255).
Immunoprecipitation studies specifically detected a single
protein band of mol. wt 185KD in SKBR-3 cells, a mam-
mary carcinoma cell line with amplified c-erbB-2. We have
used this reagent in comparative studies with 21N and have
obtained concordant results. Evaluation of membrane stain-
ing is consistent with the c-erbB-2 protein being a trans-
membrane molecule. The relevance of the cytoplasmic
staining remains uncertain. It may represent some ill-
understood receptor ligand internalisation.
DNA analysis, which allows direct assessment of gene
amplification, is a quantitative technique by which the
degree of amplification can be assessed. Immunohisto-
chemical techniques, on the other hand, can be assessed only
subjectively. This may be of considerable importance, as it is
probable that the degree of gene amplification, not merely its
presence, affects tumour behaviour. In vitro experiments on
the transforming ability of varying degrees of c-erbB-2
expression in NIH/3T3 cells suggest that the level of
product is critical in determining its transforming ability (Di
Fiore et al., 1987). Similarly, data initially suggesting that
the presence of the gene may be of prognostic importance(S-
lamon et al., 1987), was most convincing for those tumours
showing an average of at least 5 gene copies per cell.
In the present study immunohistochemical staining sugges-
tive of amplification was found in 9% of 195 primary
mammary carcinomas. No significant association was
observed between immunohistochemical staining using the
21N antibody and histological tumour type, oestrogen or
progesterone receptor status, lymph node status, menopausal
status, parity or clinical outcome measures. There was,
however, a trend for poorly differentiated (grade III) infil-
trating ductal carcinomas to show staining more often than
did grade I or II tumours.
In the study of Slamon et al. (1987) a statistically signifi-
cant association between amplification, as measured by
Southern blotting, and recurrence was observed but this was
most convincing in the lymph node positive patients showing
evidence of at least 5-fold c-erbB-2 amplification. Although
noticing a similar trend Zhou et al. (1987) did not find a
statistically significant association, in agreement with the
present study. The combination of a large number of
survivors and a small proportion of tumours showing stain-
ing means, however, that we cannot rule out the possibility
of an association between staining and survival.
It is generally agreed that c-erbB-2 amplification is not
restricted to any particular histological tumour type (Escot et
al., 1986; Gusterson et al., 1988; van de Vijver et al., 1987;
Zhou et al., 1987) and does not correlate with oestrogen
receptor status (Gusterson et al., 1988; Slamon et al., 1987;
Zhou et al., 1987). A correlation with lymph node status has
been suggested by some (Slamon et al., 1987; Zhou et al.,
1987) but not by others (Gusterson et al., 1988). Previous
studies have not shown an association between amplification
and grade III tumours (van de Vijver et al., 1987; Zhou et
al., 1987). Such conflicting results may be attributable partly
to small samples, differences in study design and the use of
different techniques to reveal c-erbB-2 gene and its product.
In the present study similar staining patterns have been
demonstrated in the in situ and infiltrating components of
mammary carcinoma. This strongly suggests an early role for
c-erbB-2 amplification in the pathogenesis of breast cancer.
It is arguable whether in a multi-step process an early event
such as this is likely to be involved in the subsequent steps
of tumour dissemination. The observation of comparable
staining in primary and secondary tumours in this study and
that of Gusterson et al. (1988) also argues against a direct
role for c-erbB-2 amplification in the process of tumour
dissemination.
Further studies are required to resolve the prognostic role
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of c-erbB-2. It is possible that c-erbB-2 amplification is
merely a marker for pathogenic amplification of a neigh-
bouring gene. A number of genes have been implicated in
the pathogenesis of breast cancer (Chan & McGee, 1987;
Escot et al., 1986; van de Vijver et al., 1987) and it is likely
that others will be found. It may well be too much to expect
any one gene to relate closely to behaviour whilst all may
contribute to the same phenotype. It has been suggested
(Bishop, 1987) that there is no evidence at present to assign
inevitable roles in tumorigenesis to individual genes.
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